Advances in therapies for glioblastomas

New therapies for recurrent glioblastomas

Glioblastomas are the most common and deadliest form of malignant primary brain tumor. Until recently, therapies for tumors that recur after standard treatment have been largely ineffective. Recent phase II studies with the humanized monoclonal antibody against vascular endothelial growth factor bevacizumab suggest that this agent is active in recurrent glioblastomas, producing response rates o...

Current status of antiangiogenic therapies for glioblastomas.

INTRODUCTION Glioblastoma (GBM), the most common primary malignant brain tumor in adults, lacks effective long-term treatment. The tumor is dependent on neovascularization for survival, making angiogenesis an attractive target for therapeutic intervention. The exact mechanism underlying the effects of antiangiogenic agents on GBM remains debatable, although it likely involves vascular endotheli...

Advances in nonpharmacologic therapies for ventricular arrhythmias

Advances in Stem Cell Therapies

Advances in Emerging Therapies 2006

The past year has seen further advancement toward the goal of effective and multifaceted stroke treatment. Encouraging evidence has emerged to support mechanical intervention for large artery occlusion, late and imagingdirected thrombolytic therapy, neuroprotectant strategies and decompressive surgery for large middle cerebral artery (MCA) stroke. We have seen important advances with regard to ...